US Reimbursement Briefs: Medicare Payments For New Drugs; 340B Rules; HHS' Best

Recent developments in US federal government regulation of prescription drug pricing and reimbursement.

HHS Building_1200

Temporary Medicare Part B payments for new drugs reduced from wholesale acquisition cost plus 6% to WAC plus 3% beginning Jan. 1, 2019, Centers for Medicare and Medicaid Services announces in Medicare physician fee schedule final rule released Nov. 1.

The change, which is described as in line with the Administration’s drug pricing agenda, is aimed at lowering beneficiary cost...

More from Pricing Debate

More from Market Access